CoChat

The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction

Ademi, Zanfina, Ofori-Asenso, Richard, Zomer, Ella, Owen, Alice, Liew, Danny · 2021 · European Journal of Preventive Cardiology

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Abstract

Aims: The aim of this study was to estimate the cost-effectiveness, from the perspective of the Australian public healthcare system, of icosapent ethyl in combination with statin therapy compared with statin alone for the prevention of cardiovascular disease. Methods and results: A Markov model populated with data from the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial was designed to predict the effectiveness and costs of icosapent ethyl in combination with statins compared with statins alone over a 20-year time horizon. Data inputs for costs and utilities were sourced from published sources. The annual costs of icosapent ethyl were assumed to be AUD1637 (USD2907) per person. All future costs and outcomes were discounted annually by 5%. The main outcome of interest was incremental cost-effectiveness ratios in terms of cost per quality adjusted life year (QALY) gained and per year of life saved (YoLS). Over a 20-year time horizon, compared with statin alone, icosapent ethyl in combination with statin was estimated to cost an additional AUD$13,022 per person, but led to 0.338 YoLS and 0.289 QALYs gained (all discounted). These equated to incremental cost-effectiveness ratios of AUD45,036 per QALY gained and AUD38,480 per YoLS. Sub-analyses for primary and secondary prevention were AUD96,136 and AUD35,935 per QALY gained, respectively. The results were sensitive to time-horizon, age related trends and the acquisition price of icosapent ethyl. Conclusion: Compared with statin alone, icosapent ethyl in combination with statin therapy is likely to be cost-effective in the prevention of cardiovascular disease assuming a willingness-to-pay threshold of AUD50,000 per QALY gained, especially in the secondary preventive setting.

Overview

Integrity signals

Registry

Crossref · 10.1177/2047487319896648

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

See all 30

Metadata

Authors
Ademi, Z., Ofori-Asenso, R., Zomer, E., Owen, A., & Liew, D.
Affiliations
  • Monash University (AU)
  • School of Public Health and Preventive Medicine, Monash University, Melbourne ,
Corresponding author
Ademi, Zanfina
Venue
European Journal of Preventive Cardiology
Published
2020-01-11
Volume
28
Issue
8
Pages
897-904
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W2998804962
Cited by
30
References
35
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 8
FWCI
4.89
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • European Journal of Preventive Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Keywords
icosapent ethyl, omega-3 fatty acids, statins, combination therapy, cardiovascular disease prevention, cost-effectiveness, incremental cost-effectiveness ratio, quality-adjusted life years, primary prevention, secondary prevention, health care costs
MeSH terms
Australia, Cardiovascular Diseases, Cost-Benefit Analysis, Humans, Markov Chains, Risk Factors, Eicosapentaenoic Acid, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. https://app.cochat.ai/papers/10.1177/2047487319896648
The paper
Ademi, Z., Ofori-Asenso, R., Zomer, E., Owen, A., & Liew, D. (2021). The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487319896648

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.